Indaptus Therapeutics

R&D

Interview at BIO 2025 with Jeffrey Meckler

Going wide on immune system activation, with Jeffrey Meckler

Indaptus CEO Jeff Meckler discusses his company's unconventional approach to immunotherapy, based on activating a wide swath of the immune system.

R&D

Jeffrey Meckler having an interview with Jonah Comstock

Reuters Pharma USA 2024 – Jeffrey Meckler

Most of the exciting work being done right now in cancer immunotherapy is centred on highly targeted approaches that aim to activate only the most necessary immune responses to eliminate a

News

After setback, Rhythm gets good news on Imcivree from FDA

Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks